ArticleGut2022
ESE3/EHF, a promising target of rosiglitazone, suppresses pancreatic cancer stemness by downregulating CXCR4.
Tianxing Zhou et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
34 papers cite it
this papercites it
ArticleGut2022
Tianxing Zhou et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.